ECSP088891A - Derivados bicíclicos como inhibidores de cetp - Google Patents

Derivados bicíclicos como inhibidores de cetp

Info

Publication number
ECSP088891A
ECSP088891A EC2008008891A ECSP088891A ECSP088891A EC SP088891 A ECSP088891 A EC SP088891A EC 2008008891 A EC2008008891 A EC 2008008891A EC SP088891 A ECSP088891 A EC SP088891A EC SP088891 A ECSP088891 A EC SP088891A
Authority
EC
Ecuador
Prior art keywords
cetp inhibitors
present
bicyclic derivatives
compounds
relates
Prior art date
Application number
EC2008008891A
Other languages
English (en)
Inventor
Eiji Kawahara
Osamu Ohmori
Ichiro Umemura
Naoko Matsuura
Masashi Kishida
Hidetomo Imase
Yuki Waki
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0609268.8A external-priority patent/GB0609268D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP088891A publication Critical patent/ECSP088891A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a novedosos compuestos de la Fórmula (I): o una composición farmacéutica de los mismos, estando todas las variables definidas en el texto. La presente invención se refiere además al uso de los compuestos de la presente para el tratamiento de, o demora de progreso para superar, las enfermedades en donde esté involucrada la proteína de transferencia de colesteril-éster.
EC2008008891A 2006-05-10 2008-11-10 Derivados bicíclicos como inhibidores de cetp ECSP088891A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0609268.8A GB0609268D0 (en) 2006-05-10 2006-05-10 Organic compounds
US86648006P 2006-11-20 2006-11-20
US89614207P 2007-03-21 2007-03-21

Publications (1)

Publication Number Publication Date
ECSP088891A true ECSP088891A (es) 2008-12-30

Family

ID=38445602

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008891A ECSP088891A (es) 2006-05-10 2008-11-10 Derivados bicíclicos como inhibidores de cetp

Country Status (17)

Country Link
US (2) US8232403B2 (es)
EP (1) EP2024356A1 (es)
KR (1) KR101172120B1 (es)
AR (1) AR060873A1 (es)
AU (1) AU2007247385B2 (es)
CA (1) CA2650954C (es)
CL (1) CL2007001325A1 (es)
CR (1) CR10420A (es)
EC (1) ECSP088891A (es)
GT (1) GT200800242A (es)
IL (1) IL195010A0 (es)
MA (1) MA30427B1 (es)
MX (1) MX2008014284A (es)
NO (1) NO20084912L (es)
TN (1) TNSN08444A1 (es)
TW (1) TW200813009A (es)
WO (1) WO2007128568A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
CA2605214C (en) 2004-12-31 2016-07-12 Reddy Us Therapeutics, Inc. Benzylamine derivatives as cetp inhibitors
KR20080086917A (ko) * 2005-12-29 2008-09-26 노파르티스 아게 콜레스테릴 에스테르 전달 단백질 (ｃｅｔｐ) 억제제로서의피리디닐 아민 유도체
US8232403B2 (en) * 2006-05-10 2012-07-31 Novartis Ag Bicyclic derivatives as CETP inhibitors
RU2008148600A (ru) * 2006-05-11 2010-06-20 Новартис АГ (CH) Производные бензиламина в качестве ингибиторов сетр
US7750019B2 (en) 2006-08-11 2010-07-06 Kowa Company, Ltd. Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
US7790737B2 (en) 2007-03-13 2010-09-07 Kowa Company, Ltd. Substituted pyrimidine compounds and their utility as CETP inhibitors
HUE024898T2 (en) * 2007-04-13 2016-02-29 Kowa Co New pyrimidine compound with dibenzylamine structure and drug containing compound
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN102300839B (zh) 2008-11-28 2014-12-10 兴和株式会社 反式-{4-[(烷基氨基)甲基]环己基}乙酸酯的制备方法
AU2010289397B2 (en) * 2009-09-03 2016-05-26 Bioenergenix Heterocyclic compounds for the inhibition of PASK
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
SG10201605304VA (en) * 2011-07-08 2016-08-30 Novartis Ag Method of treating atherosclerosis in high triglyceride subjects
EP2744803A2 (en) 2011-08-18 2014-06-25 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (cetp) inhibitors
MX352074B (es) 2011-09-27 2017-11-08 Dr Reddys Laboratories Ltd Derivados de 5-bencilaminometil-6-aminopirazolo [3,4-b] piridina como inhibidores de proteina de transferencia de ester de colesterilo (cetp) utiles para el tratamiento de aterosclerosis.
WO2014076568A2 (en) * 2012-11-19 2014-05-22 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
WO2014128564A2 (en) * 2013-02-21 2014-08-28 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
KR20160031551A (ko) 2013-07-25 2016-03-22 노파르티스 아게 심부전의 치료를 위한 시클릭 폴리펩티드
HK1218252A1 (zh) 2013-07-25 2017-02-10 Novartis Ag 合成apelin多肽之生物结合物
MA41580A (fr) 2015-01-23 2017-11-29 Novartis Ag Conjugués d'acides gras de l'apeline synthétique présentant une demi-vie améliorée
US12162863B2 (en) 2018-06-12 2024-12-10 Ryvu Therapeutics S.A. Modulators of stimulator of interferon genes (STING)
BR112021024948A2 (pt) 2019-06-12 2022-01-25 Ryvu Therapeutics S A Moduladores de próxima geração de estimulador de genes de interferon (sting)
EP4073063A1 (en) * 2019-12-11 2022-10-19 Ryvu Therapeutics S.A. Heterocyclic compounds as modulators of stimulator of interferon genes (sting)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479552B2 (en) * 1999-09-23 2002-11-12 G.D. Searle & Co. Use of substituted N, N-disubstituted diamino compounds for inhibiting cholesteryl ester transfer protein activity
PY0119496A (es) * 2000-08-07 2003-11-03 Neurogen Corp Compuestos heterociclicos como ligandos de receptores gabaa
US7332514B2 (en) * 2002-08-30 2008-02-19 Japan Tobacco Inc. Dibenzylamine compound and medicinal use thereof
AU2003291403A1 (en) 2002-11-08 2004-06-03 Neurogen Corporation 3-substituted-6-aryl pyridined as ligands of c5a receptors
JP2006521344A (ja) 2003-03-28 2006-09-21 ファイザー・プロダクツ・インク アテローム性動脈硬化症および肥満の治療のためのｃｅｔｐ阻害剤としての１，２，４−置換１，２，３，４−テトラヒドロ−および１，２−ジヒドロ−キノリンおよび１，２，３，４−テトラヒドロ−キノキサリン誘導体
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
CA2562082C (en) 2004-04-13 2013-06-25 Merck & Co., Inc. Cetp inhibitors for the treatment and prevention of atherosclerosis
JP2008520645A (ja) 2004-11-23 2008-06-19 ファイザー・プロダクツ・インク ジベンジルアミン化合物および誘導体
US7668830B2 (en) 2004-11-29 2010-02-23 Nokia Corporation Access rights
CA2605214C (en) 2004-12-31 2016-07-12 Reddy Us Therapeutics, Inc. Benzylamine derivatives as cetp inhibitors
WO2007075194A1 (en) 2005-12-28 2007-07-05 Reddy Us Therapeutics, Inc. Selective benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors
EP1834490A1 (en) 2005-01-06 2007-09-19 Thomson Licensing Reducing rainbow artifacts in digital light projection systems
WO2007007519A1 (ja) 2005-07-07 2007-01-18 Sony Corporation エバネッセント光を利用する物質情報取得方法と物質情報測定装置、並びに塩基配列決定方法と装置
WO2007008899A2 (en) 2005-07-11 2007-01-18 University Of Florida Research Foundation, Inc. Variable feathering field splitting for intensity modulated fields of large size
KR20080086917A (ko) * 2005-12-29 2008-09-26 노파르티스 아게 콜레스테릴 에스테르 전달 단백질 (ｃｅｔｐ) 억제제로서의피리디닐 아민 유도체
UY30118A1 (es) 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compueto amina trisustituido
US8232403B2 (en) * 2006-05-10 2012-07-31 Novartis Ag Bicyclic derivatives as CETP inhibitors
RU2008148600A (ru) * 2006-05-11 2010-06-20 Новартис АГ (CH) Производные бензиламина в качестве ингибиторов сетр
CN101535293A (zh) * 2006-11-15 2009-09-16 诺瓦提斯公司 作为cetp抑制剂的杂环衍生物
JP2010509388A (ja) * 2006-11-15 2010-03-25 ノバルティス アーゲー 有機化合物

Also Published As

Publication number Publication date
KR101172120B1 (ko) 2012-08-10
US8410275B2 (en) 2013-04-02
CA2650954A1 (en) 2007-11-15
TW200813009A (en) 2008-03-16
US8232403B2 (en) 2012-07-31
KR20090017580A (ko) 2009-02-18
CA2650954C (en) 2014-02-11
AR060873A1 (es) 2008-07-16
EP2024356A1 (en) 2009-02-18
AU2007247385B2 (en) 2011-07-14
IL195010A0 (en) 2009-08-03
US20120225874A1 (en) 2012-09-06
GT200800242A (es) 2009-04-29
CR10420A (es) 2009-02-02
US20090227580A1 (en) 2009-09-10
NO20084912L (no) 2009-02-03
AU2007247385A1 (en) 2007-11-15
TNSN08444A1 (en) 2010-04-14
WO2007128568A1 (en) 2007-11-15
MX2008014284A (es) 2008-11-18
MA30427B1 (fr) 2009-05-04
CL2007001325A1 (es) 2008-07-18

Similar Documents

Publication Publication Date Title
ECSP088891A (es) Derivados bicíclicos como inhibidores de cetp
BRPI0721905B8 (pt) composto inibidor de proteassoma, sua composição farmacêutica e seu uso
SV2008003045A (es) Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes
NI201100081A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa - iv para el tratamiento o prevención de diabetes.
ECSP099370A (es) Derivados de hidantoína usados como inhibidores de mmp
ECSP11011011A (es) Derivados de acido 1-amino-2-ciclobutiletilborónico
SV2011003855A (es) Heteroarilos sustituidos
EA201170772A1 (ru) Органические соединения
GT201000023A (es) Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met.
BRPI0911105A2 (pt) compostos contendo um farmacóforo anti-inflamatório, composição farmacêutica, bem como seu uso
UY32848A (es) Compuestos heterocíclicos de oxima
CR10356A (es) Derivados de 4-benzilphthalazinona 2-sustituidos como antagonistas de histamina h1 y h3
UY33337A (es) DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
UY30481A1 (es) Isoxazolinas sustituidas, composiciones farmaccuticas que contienen a las mismas, metodos de preparacion y usos.
CR10875A (es) Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides
GT201400031A (es) Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2
ECSP088414A (es) Derivados de ácido bifeniloxiacético para el tratamiento de una enfermedad respiratoria
MA32723B1 (fr) Derives d'anilino-pyrimidine a substitution sulfoximine en tant qu'inhibiteurs de cdk, leur preparation et leur utilisation comme medicaments
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
DOP2006000061A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
CL2007003223A1 (es) Compuestos derivados de piperidinil 4-arilsulfonamidas n-sustituidas, que actuan como moduladores de la proteina sfrp-1; proceso para preparar los compuestos; co mposicion farmaceutica que comprende a dichos copmpuestos y uso de los compuestos para preparar medicamentos para el tratamiento de enfermedades.
DOP2006000017A (es) Pirazolopiridinas y sales de las mismas, una composición farmaceútica que comprende dichos compuestos, un método para prepararlos y su uso
UY30862A1 (es) Derivados de piridopirimidina, composiciones farmacéuticas conteniéndolos, procesos de preparacioon y aplicaciones
UY29294A1 (es) Sulfonamido-macrocíclos y sus sales como inhibidoras de tie2, composición farmacéutica que comprende estos compuestos, método de prepararlos y su uso.
EA200802000A1 (ru) Фармацевтически приемлемые соли и полиморфные формы